Athira Pharma Insiders Placed Bullish Bets Worth US$556.3k
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Athira Pharma, Inc. (NASDAQ:ATHA), it sends a favourable message to the company's shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for Athira Pharma
Athira Pharma Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by CFO & Chief Business Officer Andrew Gengos for US$192k worth of shares, at about US$3.02 per share. That means that even when the share price was higher than US$1.52 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
In the last twelve months Athira Pharma insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Athira Pharma
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Athira Pharma insiders own 7.3% of the company, worth about US$4.3m. We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Athira Pharma Insiders?
The fact that there have been no Athira Pharma insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if Athira Pharma insiders bought more shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Athira Pharma. When we did our research, we found 4 warning signs for Athira Pharma (2 can't be ignored!) that we believe deserve your full attention.
But note: Athira Pharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
